查看購物車
  • English
  • Japanese
  • Korean
先天性高胰島素血症治療市場規模、佔有率和成長分析：按療法、藥物、疾病、給藥途徑、最終用戶、病患小組和地區分類－2026-2033年產業預測
市場調查報告書
商品編碼
2078815

先天性高胰島素血症治療市場規模、佔有率和成長分析：按療法、藥物、疾病、給藥途徑、最終用戶、病患小組和地區分類－2026-2033年產業預測

Congenital Hyperinsulinism Treatment Market Size, Share, and Growth Analysis, By Treatment Type, By Drug Type, By Disease Type, By Route of Administration, By End User, By Patient Group, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2024 年全球先天性高胰島素血症治療市場價值為 1.43 億美元，預計到 2033 年將成長至 2.4365 億美元，而 2025 年為 1.5172 億美元，預測期（2026-2033 年）複合年成長率為 6.1%。

先天性高胰島素血症 (CH) 治療的全球市場正經歷顯著成長，這主要得益於診斷技術的進步、保險報銷制度的改革以及個人化醫療的發展。保險公司越來越支持難治性 CH 患者採用新的治療方案，這降低了藥物成本，並促使醫生推遲手術干預，例如在嘗試所有藥物療法之前進行近全胰切除術。這種轉變正在拓展Octreotide類似物的治療應用。真實世界數據顯示，隨著醫保覆蓋藥物的可及性提高，手術量顯著減少，這促使製藥公司在歐洲和日本等地區尋求孤兒藥資格認定。因此，在市場進入改善、產品線多元化以及政策主導的需求成長的推動下，CH 市場預計將以 12% 的強勁複合年成長率 (CAGR) 成長。

全球先天性高胰島素血症治療市場的成長要素

基因篩檢的不斷擴展正在加速先天性高胰島素血症的早期發現，從而實現及時的治療性介入。快速診斷為有效控制病情提供了契機，無論是透過藥物治療或手術干預，都能改善患者預後並減少長期健康問題。隨著醫療專業人員對高胰島素血症的多種治療方案的了解加深，他們更有可能開立合適的藥物。此外，患者及其家屬能夠獲得更準確的新療法預後數據，從而提高他們對這些創新療法的接受度。這些因素共同推動了先天性高胰島素血症治療市場的成長：擴大了符合先進治療條件的患者群體，增強了醫生在兒童患者高胰島素血症治療方面的信心，並鼓勵醫療系統加大對專科護理的投入。

全球先天性高胰島素血症治療市場面臨的限制因素

由於發展中國家缺乏有效的治療方法，全球先天性高胰島素血症治療市場的成長面臨嚴峻挑戰。許多中低收入國家缺乏必要的診斷資源，導致疾病識別延遲，漏診率較高。這些地區的醫療衛生系統通常優先關注糖尿病和癌症等常見疾病的治療，而對罕見內分泌疾病的關注度較低。因此，患者的治療選擇有限，醫療專業人員也可能對最新的治療方法不夠了解。這些准入限制不僅阻礙了市場滲透，也阻礙了治療方法的廣泛應用，從而影響了該領域在全球範圍內的未來成長前景。

先天性高胰島素血症治療的全球市場趨勢

受基因組學進步的推動，全球先天性高胰島素血症治療市場正經歷著向精準醫療的重大轉變。次世代定序在臨床實踐中的應用，使醫療專業人員能夠根據患者的基因譜制定個人化的治療策略，並區分疾病的局限型和瀰漫型。這項轉變減少了對試驗誤療法的依賴，簡化了診斷流程，並最佳化了治療效果。製藥公司正日益調整開發平臺，以針對特定基因型，並與學術機構合作建立註冊登記系統，用於評估真實臨床環境中的治療效果。這些趨勢共同提升了改善先天性高胰島素血症患者照護和治療效果的潛力。

目錄

介紹

  • 調查目的
  • 市場定義和範圍

調查方法

  • 研究過程
  • 二級資料和一級資料的方法
  • 市場規模估算方法

執行摘要

  • 全球市場展望
  • 市場主要亮點
  • 細分市場概覽
  • 競爭環境概述

市場動態及展望

  • 總體經濟指標
  • 促進者和機會
  • 抑制因素和挑戰
  • 供給面趨勢
  • 需求面趨勢
  • 波特的分析和影響

關鍵市場分析

  • 關鍵成功因素
  • 影響市場的因素
  • 主要投資機會
  • 生態系測繪
  • 2025年市場魅力指數
  • PESTLE分析
  • 監理情勢
  • 疾病流行病學

全球先天性高胰島素血症治療市場規模：依治療類型分類

  • 藥物治療
  • 手術治療
  • 營養管理
  • 基於基因的療法和新興療法

全球先天性高胰島素血症治療藥物市場規模：依藥物類型分類

  • 二氮嗪
  • Octreotide
  • Lanreotide
  • 升糖素
  • 其他

全球先天性高胰島素血症治療市場規模：依疾病類型分類

  • 局部性先天性高胰島素血症
  • 瀰漫性先天性高胰島素血症
  • 非典型先天性高胰島素血症

全球先天性高胰島素血症治療藥物市場規模：依給藥途徑分類

  • 口服
  • 注射藥物
  • 靜脈

全球先天性高胰島素血症治療市場規模：依最終用戶分類

  • 醫院
  • 兒童內分泌中心
  • 專科診所
  • 學術研究機構

全球先天性高胰島素血症治療市場規模：依病患小組分類

  • 新生
  • 嬰兒
  • 孩子們

全球先天性高胰島素血症治療市場規模：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太國家
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲國家
  • 中東和非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

競爭資訊

  • 前五大公司對比
  • 主要公司2025年的市場定位
  • 主要市場公司採取的策略
  • 近期市場趨勢
  • 企業市場占有率分析，2025 年
  • 主要公司的完整公司簡介
    • 公司詳情
    • 產品系列分析
    • 按細分市場進行企業市佔率分析
    • 銷售收入年比比較（2023-2025 年）

主要公司簡介

  • Rezolute, Inc.
  • Zealand Pharma A/S
  • Hanmi Pharmaceutical Co., Ltd.
  • Crinetics Pharmaceuticals, Inc.
  • Recordati SpA
  • Ascendis Pharma A/S
  • BridgeBio Pharma, Inc.
  • Ultragenyx Pharmaceutical Inc.
  • Travere Therapeutics, Inc.
  • Xeris Biopharma Holdings, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Amolyt Pharma SAS
  • Advanz Pharma Corp. Limited
  • Eton Pharmaceuticals, Inc.
  • Amylyx Pharmaceuticals, Inc.
  • Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Merck & Co., Inc.

結論與建議

簡介目錄
Product Code: SQMIG35H2594

Global Congenital Hyperinsulinism Treatment Market size was valued at USD 143.00 Million in 2024 and is poised to grow from USD 151.72 Million in 2025 to USD 243.65 Million by 2033, growing at a CAGR of 6.1% during the forecast period (2026-2033).

The global Congenital Hyperinsulinism (CH) treatment market is experiencing significant growth fueled by advancements in diagnostics, reimbursement reforms, and personalized medicine initiatives. Insurers are increasingly supporting novel therapeutic options for patients with refractory CH, lowering medication costs and encouraging physicians to delay surgical interventions like near-total pancreatectomy until all drug therapies have been explored. This shift has extended the therapeutic use of octreotide analogues. Real-world data indicates a notable reduction in surgical procedures following improved access to reimbursed drug therapy, prompting manufacturers to seek orphan drug status in regions such as Europe and Japan. Consequently, the CH market is projected to expand at a robust CAGR of 12%, driven by enhanced market access, a diverse pipeline, and growing policy-driven demand.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Congenital Hyperinsulinism Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Congenital Hyperinsulinism Treatment Market Segments Analysis

Global congenital hyperinsulinism treatment market is segmented by treatment type, drug type, disease type, route of administration, end user, patient group and region. Based on treatment type, the market is segmented into drug therapy, surgical treatment, nutritional management and gene-based & emerging therapies. Based on drug type, the market is segmented into diazoxide, octreotide, lanreotide, glucagon and others. Based on disease type, the market is segmented into focal congenital hyperinsulinism, diffuse congenital hyperinsulinism and atypical congenital hyperinsulinism. Based on route of administration, the market is segmented into oral, injectable and intravenous. Based on end user, the market is segmented into hospitals, pediatric endocrinology centers, specialty clinics and academic & research institutes. Based on patient group, the market is segmented into neonates, infants and children. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Congenital Hyperinsulinism Treatment Market

The expansion of genetic screening initiatives facilitates the early identification of congenital hyperinsulinism, enabling timely therapeutic interventions. Prompt diagnoses create opportunities for effective management of the condition, whether through pharmacological treatments or surgical procedures, leading to improved patient outcomes and a decrease in long-term health issues. As healthcare providers become more knowledgeable about the myriad treatment options available for hyperinsulinism, they are increasingly likely to prescribe appropriate medications. Additionally, patients and their families gain access to improved prognostic data regarding new therapies, which fosters greater acceptance of these innovative approaches. Collectively, these elements expand the patient population eligible for advanced treatments, bolster physician confidence in managing hyperinsulinism in pediatric patients, and encourage healthcare systems to invest in specialized care, thereby driving the growth of the market for congenital hyperinsulinism treatments.

Restraints in the Global Congenital Hyperinsulinism Treatment Market

The growth of the global congenital hyperinsulinism treatment market faces significant challenges due to the scarcity of available therapies in developing regions. Many low- and middle-income countries lack essential diagnostic resources, leading to delays in identifying the condition and a higher likelihood of missed diagnoses. Healthcare systems in these areas typically prioritize the management of more prevalent diseases, such as diabetes and cancer, which results in a diminished focus on rare endocrine disorders. Consequently, patients have fewer treatment alternatives, and healthcare professionals may not be well-versed in the latest therapeutic options. This limited accessibility not only hampers market penetration but also restricts adoption and impedes future growth prospects on a global scale.

Market Trends of the Global Congenital Hyperinsulinism Treatment Market

The global market for congenital hyperinsulinism treatment is witnessing a significant shift towards precision medicine, driven by advancements in genomics. The integration of next-generation sequencing into clinical practice enables healthcare professionals to tailor treatment strategies based on the patient's genetic profile, distinguishing between focal and diffuse forms of the condition. This evolution reduces reliance on trial-and-error methods, streamlining diagnosis and optimizing therapeutic outcomes. Pharmaceutical companies are increasingly aligning their development pipelines to target specific genotypes, collaborating with academic institutions and creating registries to assess real-world treatment efficacy. These trends collectively enhance the potential for improved patient care and outcomes in the congenital hyperinsulinism landscape.

Table of Contents

Introduction

  • Objectives of the Study
  • Market Definition & Scope

Research Methodology

  • Research Process
  • Secondary & Primary Data Methods
  • Market Size Estimation Methods

Executive Summary

  • Global Market Outlook
  • Key Market Highlights
  • Segmental Overview
  • Competition Overview

Market Dynamics & Outlook

  • Macro-Economic Indicators
  • Drivers & Opportunities
  • Restraints & Challenges
  • Supply Side Trends
  • Demand Side Trends
  • Porters Analysis & Impact
    • Competitive Rivalry
    • Threat of Substitute
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factors
  • Market Impacting Factors
  • Top Investment Pockets
  • Ecosystem Mapping
  • Market Attractiveness Index 2025
  • PESTEL Analysis
  • Regulatory Landscape
  • Disease Epidemiology

Global Congenital Hyperinsulinism Treatment Market Size by Treatment Type & CAGR (2026-2033)

  • Market Overview
  • Drug Therapy
  • Surgical Treatment
  • Nutritional Management
  • Gene-Based & Emerging Therapies

Global Congenital Hyperinsulinism Treatment Market Size by Drug Type & CAGR (2026-2033)

  • Market Overview
  • Diazoxide
  • Octreotide
  • Lanreotide
  • Glucagon
  • Others

Global Congenital Hyperinsulinism Treatment Market Size by Disease Type & CAGR (2026-2033)

  • Market Overview
  • Focal Congenital Hyperinsulinism
  • Diffuse Congenital Hyperinsulinism
  • Atypical Congenital Hyperinsulinism

Global Congenital Hyperinsulinism Treatment Market Size by Route of Administration & CAGR (2026-2033)

  • Market Overview
  • Oral
  • Injectable
  • Intravenous

Global Congenital Hyperinsulinism Treatment Market Size by End User & CAGR (2026-2033)

  • Market Overview
  • Hospitals
  • Pediatric Endocrinology Centers
  • Specialty Clinics
  • Academic & Research Institutes

Global Congenital Hyperinsulinism Treatment Market Size by Patient Group & CAGR (2026-2033)

  • Market Overview
  • Neonates
  • Infants
  • Children

Global Congenital Hyperinsulinism Treatment Market Size & CAGR (2026-2033)

  • North America (Treatment Type, Drug Type, Disease Type, Route of Administration, End User, Patient Group)
    • US
    • Canada
  • Europe (Treatment Type, Drug Type, Disease Type, Route of Administration, End User, Patient Group)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Treatment Type, Drug Type, Disease Type, Route of Administration, End User, Patient Group)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Treatment Type, Drug Type, Disease Type, Route of Administration, End User, Patient Group)
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Treatment Type, Drug Type, Disease Type, Route of Administration, End User, Patient Group)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Rezolute, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Zealand Pharma A/S
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hanmi Pharmaceutical Co., Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Crinetics Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Recordati S.p.A.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ascendis Pharma A/S
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BridgeBio Pharma, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ultragenyx Pharmaceutical Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Travere Therapeutics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Xeris Biopharma Holdings, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Rhythm Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amolyt Pharma SAS
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Advanz Pharma Corp. Limited
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eton Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amylyx Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hoffmann-La Roche Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations